Oncocyte (IMDX) versus Its Rivals Head to Head Comparison

Oncocyte (NASDAQ:IMDX) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Oncocyte to related businesses based on the strength of its dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Oncocyte and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Oncocyte Competitors	-12,359.35%	-203.09%	-30.93%

Risk and Volatility

Oncocyte has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, Oncocyte’s rivals have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Valuation & Earnings

This table compares Oncocyte and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncocyte	$1.67 million	-$50.22 million	-1.64
Oncocyte Competitors	$715.82 million	$12.57 million	-10.86

Oncocyte’s rivals have higher revenue and earnings than Oncocyte. Oncocyte is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

55.3% of Oncocyte shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 2.2% of Oncocyte shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Oncocyte and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Oncocyte Competitors	9793	15079	45386	1576	2.54

Oncocyte presently has a consensus price target of $10.50, indicating a potential upside of 329.27%. As a group, “Biotechnology” companies have a potential upside of 103.14%. Given Oncocyte’s higher probable upside, research analysts plainly believe Oncocyte is more favorable than its rivals.

Summary

Oncocyte beats its rivals on 7 of the 13 factors compared.

About Oncocyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.